November 30, 2011
Ono Pharmaceutical announced on November 30 that the US FDA has accepted an NDA for carfilzomib, a next-generation proteasome inhibitor the company licensed from Onyx Pharmaceuticals of the US in September. Onyx is seeking an indication for relapsed or refractory...read more